Company profile for Monopar Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The Company's pipeline consists of Validive® for the potential prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the potential treatment of advanced soft tissue sarcoma; and a late-stage precli...
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The Company's pipeline consists of Validive® for the potential prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the potential treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101. For more information visit: www.monopartx.com.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1000 Skokie Blvd. Suite 350 Wilmette, IL 60091
Telephone
Telephone
(847) 388-0349
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/13/3187279/0/en/Monopar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Developments.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/09/3184138/0/en/Monopar-Presents-New-Data-and-Analyses-on-Rapidly-Improved-Copper-Balance-in-Wilson-Disease-Patients-on-Tiomolybdate-Choline-at-AASLD-The-Liver-Meeting-2025.html

GLOBENEWSWIRE
09 Nov 2025

https://www.globenewswire.com/news-release/2025/10/15/3167014/0/en/Monopar-Announces-Abstract-Accepted-for-Oral-Presentation-at-AASLD-The-Liver-Meeting-2025.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/09/14/3149528/0/en/Monopar-to-Present-New-Long-Term-Neurological-Efficacy-and-Safety-Data-for-ALXN1840-in-Wilson-Disease-at-the-150th-American-Neurological-Association-Annual-Meeting.html

GLOBENEWSWIRE
14 Sep 2025

https://www.globenewswire.com/news-release/2025/09/03/3143522/0/en/Monopar-Announces-Abstract-Accepted-with-Distinction-for-Oral-and-Poster-Presentations-at-the-Upcoming-American-Neurological-Association-2025-Annual-Meeting.html

GLOBENEWSWIRE
03 Sep 2025

https://www.globenewswire.com/news-release/2025/08/12/3131621/0/en/Monopar-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Developments.html

GLOBENEWSWIRE
12 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty